Commense Bio
Commense Bio
  • Home
  • Team
  • Technology
  • Pipeline
  • More
    • Home
    • Team
    • Technology
    • Pipeline
  • Home
  • Team
  • Technology
  • Pipeline

Technology

Invasive Bacterial Infections Lead to Morbidity and Mortality, with Infection Control Representing a

In the U.S. alone, healthcare associated bacterial infections result in more than 100,000 deaths and costs of roughly $45 billion annually. Specifically, S. aureus has become one of the most common reasons for healthcare visits. Expenditures on S. aureus infections in the U.S. are estimated to be $15 billion. the long-term use of antibiotics is not recommended by the Infectious Diseases of America (IDSA) for prevention of recurrent disease due to the increasing risk of developing antimicrobial resistance (AMR).

Centers for Disease Control and Prevention

According to the Centers for Disease Control and Prevention, 35,000 deaths per year in the U.S. are due to AMR. Direct healthcare costs for AMR have reached $20 billion.

World Health Organization

The World Health Organization has declared antimicrobial resistance "one of the most urgent threats."

Not Just a New Treatment — A Fundamentally Novel Therapeutic

Commense Bio is utilizing differentiated, cutting-edge biology to engineer optimized bacterial strains that physically occupy the skin microbiome to durably prevent undesired colonization. Our genetically-modified live biotherapeutics exert their mechanism of action through bacterial interference which involves the use of one bacterial species to prevent the growth of a second disease-causing bacterial.

Learn More About Our Investigational Approach

  • Contact Us

Commense Bio

Copyright © 2026 Commense Bio - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept